Emergent and HHS Agree to End CIADM Arrangement
Emergent BioSolutions (NYSE: EBS) and the U.S. Department of Health and Human Services (HHS) have mutually agreed to Emergent’s proposal to end its involvement in the Centers for Innovation in Advanced Development and Manufacturing (CIADM) program. This agreement with HHS also wraps up and closes out all open obligations and task orders issued under the CIADM base contract.
The Obama-Biden Administration initiated the CIADM program as recognition of the shortage of domestic manufacturing capability needed to respond to an unforeseen, widespread public health threat following the H1N1 influenza pandemic. While a logical and innovative idea, subsequent execution of the CIADM program and operational investment by all administrations fell short of what was needed to maintain capability in case such a threat arose.
Emergent was just one of two original partners to remain in the CIADM program and respond to the COVID-19 pandemic. We are proud of the work our employees have done over the past nine years to honor our commitments, and especially proud of the work we did through the program to address Zika, Ebola, and most recently COVID-19 across several of our manufacturing facilities. We have also acknowledged the challenges we faced scaling up production of two novel, viral-vector COVID-19 vaccines in the same facility and addressed them with our fellow innovators as well as the FDA and other health regulators.
While no longer part of the CIADM program, we remain a committed partner to the federal government supplying needed medical countermeasures and other solutions for our most serious public health threats, and we look forward to sharing our experience to help inform America’s planning for future public health threats.
Emergent will continue working with its commercial partner Johnson & Johnson to produce their COVID-19 vaccine at our Bayview facility, as this work is not and has not been a part of the CIADM arrangement.